These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease. Vishwas S; Awasthi A; Corrie L; Kumar Singh S; Gulati M Med Hypotheses; 2020 Oct; 143():109879. PubMed ID: 32474382 [TBL] [Abstract][Full Text] [Related]
68. Prescribing trends in cognition enhancing drugs in Australia. Hollingworth SA; Byrne GJ Int Psychogeriatr; 2011 Mar; 23(2):238-45. PubMed ID: 20670461 [TBL] [Abstract][Full Text] [Related]
71. The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias. Fillit H; Hill J Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S24-9. PubMed ID: 15249845 [TBL] [Abstract][Full Text] [Related]
72. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890 [TBL] [Abstract][Full Text] [Related]
73. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Lachaine J; Beauchemin C; Legault M; Bineau S Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692 [TBL] [Abstract][Full Text] [Related]
74. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169 [TBL] [Abstract][Full Text] [Related]
76. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Whitehouse PJ; Winblad B; Shostak D; Bhattacharjya A; Brod M; Brodaty H; Dor A; Feldman H; Forette F; Gauthier S; Hay J; Henke C; Hill S; Mastey V; Neumann P; O'Brien B; Pugner K; Sano M; Sawada T; Stone R; Wimo A Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):266-80. PubMed ID: 9876955 [TBL] [Abstract][Full Text] [Related]
77. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia. Versijpt J J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049 [TBL] [Abstract][Full Text] [Related]
78. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Green C Pharmacoeconomics; 2007; 25(9):735-50. PubMed ID: 17803333 [TBL] [Abstract][Full Text] [Related]